贝伐单抗在复发性卵巢癌治疗的研究进展

Research progress of bevacizumab in the treatment of recurrent ovarian cancer

卵巢癌(Ovarian cancer,OC)由于易出现复发和铂耐药现象,给临床治疗带来极大困难。近年来,大量的试验结果表明,贝伐单抗作为抗血管生成药物能明显改善卵巢癌患者的预后。本文通过简述贝伐单抗的抗肿瘤机制,对其单药和联合治疗复发性卵巢癌的最新进展进行了详细介绍,并提出肿瘤标志物的联合检测及个体化精准治疗将是未来主要的发展方向。

cancer(OC)is prone to recurrence and platinum resistance,which makes clinical treatment extremely difficult.In recent years,a large number of trials have shown that bevacizumab as an anti-angiogenic drug can significantly improve the prognosis of ovarian cancer patients.In this paper,the anti-tumor mechanism of bevacizumab is briefly described,the latest progress of its monotherapy and combination therapy for recurrent ovarian cancer is introduced in detail,and the combined detection of tumor markers and individualized precision therapy will be the main development direction in the future.